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introduction
What Will It Take to
Address the Global Threat of
Antibiotic Resistance?
Steven J. Hoffman and Kevin Outterson

O

f the many global health challenges facing
the world today, only a small number require
global collective action. Most health challenges can be fully addressed through action at local,
regional or national levels.
What kind of actions must be taken to address the
global threat of antibiotic resistance (ABR)? What
legal, political and economic tools might be needed to
achieve this level of action?
In March 2015 the Dag Hammarskjöld Foundation1
convened a workshop in Uppsala, Sweden to address
these questions in partnership with the Global Strategy Lab,2 the Journal of Law, Medicine & Ethics
(JLME),3 the Norwegian Institute of Public Health,4
and ReAct – Action on Antibiotic Resistance.5 Eleven
concise articles were commissioned to explore whether
ABR depended on global collective action, and if so,
what tools could help states and non-state actors to
achieve it. This work built upon previous efforts of the
Dag Hammarskjöld Foundation and its partners to
address ABR, as well as instigate further research that
is needed to inform relevant global policies, initiatives,
and actions going forward.
Steven J. Hoffman, B.H.Sc., M.A., J.D., is an Associate
Professor of Law and Director of the Global Strategy Lab at
the University of Ottawa with courtesy appointments as an
Assistant Professor of Clinical Epidemiology & Biostatistics
(Part-Time) at McMaster University and Adjunct Associate
Professor of Global Health & Population at Harvard University. He previously worked for the Ontario Ministry of
Health & Long-Term Care, World Health Organization, and
the Executive Office of the United Nations Secretary-General.
Kevin Outterson, J.D., LL.M., is a Professor of Law and the
N. Neal Pike Scholar in Health and Disability Law at Boston
University School of Law, an Associate Fellow at Chatham
House, and the Editor-in-Chief of the Journal of Law, Medicine & Ethics.
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The Problem of Antibiotic Resistance
This peer-reviewed JLME series begins with a detailed
description of ABR. The medical evidence is clear that
antibiotic resistance spreads across borders through
many vectors. Tamar Barlam and Kalpana Gupta
highlight the medical evidence that underpins the
conclusion that resistance is a transnational health
risk and thus a truly global problem.6 Even countries
with extraordinary programs in antibiotic stewardship can face multi-drug resistant diseases when a
traveler returns home from abroad.
While medical evidence is central to this effort, narrow disciplinary perspectives can hinder a full view of
the field. To a physician, ABR is salient when a patient
in the intensive care ward develops an untreatable
and deadly bacterial infection. The problem is a lack
of new drugs and the solution is to develop new treatments. To an infection control specialist, the problem
is the nosocomial transmission of multi-drug resistant
pathogens in hospitals. Solutions include better hospital infection control, including active surveillance.
Public health officials might look even further back, at
the chain of events that allowed multi-drug resistant
bacteria to evolve due to improper antibiotic stewardship, including perhaps indiscriminate use of antibiotics among both humans and animals.
None of these disciplinary perspectives are wrong,
but they give a limited view of a complex systems
problem. For this reason, we sought from the beginning to include people from diverse academic and
professional disciplines in this project, including physicians, public health practitioners, epidemiologists,
economists, historians, lawyers, political scientists,
and social activists — all of whom were committed to
advancing global health, especially among the poorest
populations on the planet. ABR is a complex problem,
journal of law, medicine & ethics
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Figure 1
Policy Tripod for Addressing Antibiotic Resistance

Access without
conservation and
innovation will speed
resistance
Conservation
constrains access
and undermines
Innovation

Innovation
without access
is unjust, and
without
conservation
it’s wasteful.

one best addressed through interdisciplinary work
including academics, clinicians and policymakers
across varied contexts.
Our interdisciplinary approach yielded a threepronged approach to tackling ABR: (1) Access, (2)
Conservation, and (3) Innovation (see Figure 1).7
Access, or lack thereof, is the cause of more people dying today from susceptible bacteria than from
resistant bacterial pathogens,8 despite warnings of
a looming antibiotic apocalypse.9 Inadequate access
to existing antibiotics is a global health crisis of the
first order that currently receives insufficient attention. But antibiotic access cannot stand alone as a
solution. Promoting global access to antibiotics will
speed resistance unless it is coupled with strong conservation programs to ensure appropriate use. Access
and conservation themselves may actually work at
cross-purposes unless integrated into a single program. In addition, achieving universal access for
low- and middle-income populations could undermine commercial incentives to invest in the research
and development (R&D) necessary to bring innovative new antibiotics to market. The article by Nils
Daulaire and colleagues takes a bold stance on the
crisis of antibiotic access, but they also recognize the
imperative to integrate the solution with both conservation and innovation. While access could possibly be addressed on a country-by-country basis,
an integrated solution requires coordinated action
across borders.

Our interdisciplinary
approach yielded a threepronged approach to
tackling ABR: (1) Access,
(2) Conservation, and (3)
Innovation.

Conservation cannot stop resistance, but it can certainly slow the rate of the emergence and spread of
multi-drug resistant organisms. Conservation slows
the rate of bacterial evolution, buying us time to
develop alternatives. Conservation also includes activities that are welcome even in the absence of resistance
because preventing an infection is always better than
treating one. Public health measures like vaccines,
clean food, safe drinking water, and infection control
all support conservation by reducing the demand for
antibiotics in the first instance.10 But conservation,
despite many positive attributes, also faces obstacles.
Conservation attempts to limit the inappropriate use
of antibiotics, but the difficulty lies in defining “inappropriate,” including use in resource-poor settings
where access is the most pressing problem. Furthermore, conservation programs reduce the demand for
antibiotics, which may encourage pharmaceutical and
biotechnology companies to flee the field. Few companies want to step up R&D investments in a declining market. Most importantly, conservation is a global
collective action problem: while most conservation
efforts will be implemented nationally, they work
best when every country participates. For some countries, financial support will be necessary, as recently
articulated in the World Health Organization’s Global
Action Plan on Antimicrobial Resistance.11
Innovation is the third leg of the tripod. We clearly
need new antibiotic drugs to tackle emerging multidrug resistant diseases and the market is not responding adequately to the challenge.12 Traditional drug
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innovation models would promote either higher prices
or larger volumes in order to drive innovation, but for
antibiotics, the first would constrain access and the
latter might undermine conservation. Crafting an
effective new innovation model for antibiotics is necessarily a global endeavor, as described in this series
by Manica Balasegaram, Charles Clift, and John-Arne
Røttingen.13 They propose new global institutional
arrangements to fund R&D and reward innovation for
antibiotics, harmonized with the goals of access and
conservation.

Learning from Different Perspectives
To broaden our understanding of the problem, this
series also explores four additional disciplinary perspectives on ABR, rooted in history, economics, “One
Health,” and the environment. The recent work on the
history of antibiotics is vibrant, woven together in the
article by Scott Podolsky and colleagues.14 The antibiotic era is only seven decades old, but our collective
memories need refreshing. Most salient to the present
efforts are issues of who controls the use of antibiotics. Conservation and stewardship programs today are
marching into prescriber autonomy battles that have
been underway for decades in many settings. They
also remind us that the current regulatory regime for
prescription drugs was largely a response to problems
with safety and efficacy of antibiotics. This is a timely
reminder since the U.S. Food & Drug Administration
and European Medicines Agency have greatly relaxed
those standards in recent years, specifically to boost
antibiotic innovation.
Three key points arise from the economic analysis
by Aidan Hollis and Peter Maybarduk.15 First, antibiotics are a global public good and the solution must
address the “commons” problem. If we treated antibiotics as uniquely valuable and exhaustible, we would
stop using them in low-value ways like animal growth
promotion and human viral infections. Second, from
an economics perspective, addressing the triad of
access, conservation and innovation requires global
coordination, as national-level solutions would be vulnerable to free riding, perverse financial incentives,
and inadequate commitment mechanisms. Finally,
they apply the work of Elinor Ostrom on the design
and governance of coalitions to manage commons to
emerging global governance options for antibiotics.
The One Health movement seeks to understand the
many linkages between human and animal health,
integrating approaches to improve planetary health.
The task given to Anthony So and colleagues was
expansive, and could easily have been the subject of
its own series. But the primary message shines clearly
through the mounds of data: human health and ani8

mal health are deeply intertwined and therefore any
solution to ABR must include, as a core component,
animal health.16 It might be tempting to “simplify”
the solution by cabining animal issues in a separate
response, but that would be a profound mistake.
The final perspective article by Steinar Andresen
and Steven J. Hoffman reminds us that ABR is not
the only global collective action problem and that we
have much to learn from how other sectors address
“commons” problems like it.17 Their article benefits
from the decades that Andresen has spent studying
multilateral environmental agreements, first relating
to oceans and more recently to climate change. They
argue that while the international system is inherently
weak, states can craft agreements to achieve global
collective action if they are designed appropriately. In
other words, institutional design matters. Learning
from the environment, effective agreements include
good procedures for reporting, enhancing compliance,
and supporting implementation. Non-state actors
must be engaged and mixed legal/political approaches
should be considered.

Moving Towards Global Collective Action
The series ends with four articles that explore the
mechanisms, instruments and forums available to
states for achieving global collective action on ABR.
Steven J. Hoffman and Trygve Ottersen highlight the
need to put accountability at the core of any international agreement for it to achieve real-world impact.18
They start by defining “accountability” — a term used
too often in so many different ways — as a relationship involving answerability and enforceability. Building on this definition, they sketch out a taxonomy of
accountability mechanisms covering transparency,
oversight, complaint and enforcement. This taxonomy
then serves as a menu of options for global decisionmakers to embed accountability into the core of any
kind of international agreement, either for ABR or
other issues. Like guests at a restaurant, they do not
recommend ordering every item from the menu. That
might be unhealthy. But in the absence of empirical
studies evaluating each mechanism’s effectiveness,
they advise global decision-makers to incorporate at
least one mechanism from each category and rigorously evaluate their impact.
Questions around the exact kind of international
instrument needed to address ABR are taken up in
the next article by Steven J. Hoffman, John-Arne Røttingen and Julio Frenk, who make a strong argument
in favor of pursuing an international legal approach.19
Whereas all three co-authors have previously taken
stands against the adoption of new global health
laws,20 they see something different in ABR. Specifijournal of law, medicine & ethics
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cally, they think it is the only health challenge for which
an international legal approach has thus far been proposed whereby (1) the problem has a significant transnational dimension, (2) the solution justifies the use of
an instrument with coercive features, (3) the outcome
of utilizing international law is likely beneficial, and
(4) the implementation of needed actions have not
been achieved through other instruments. These four
features, which the trio put forward elsewhere as a cri-

priate convening forum for pursing it will need to be
made. Zain Rizvi and Steven J. Hoffman argue that
just as much attention should be given to how and
where global collective action on ABR is facilitated as
the specific actions that are needed.23 This is because
the success of any international agreement depends
greatly on where it is negotiated and implemented. In
their article, the two co-authors evaluate four different
forums though which states could develop an interna-

Our goal for this series was to start providing evidence-informed guidance
for how states and non-state actors could muster a comprehensive
response to the global threat of ABR — addressing the access, conservation
and innovation imperatives — while inspiring new lines of inquiry. We
acknowledge this work is only a start because we know that much additional
research and analysis is needed. Our real innovation here is having taken
a scientific approach to global strategy whereby we drew upon a range
of disciplines to systematically assess how instruments, institutions and
initiatives could be designed to foster collective action on ABR and maximize
impact. Our hope is that many more researchers, policymakers, activists, and
social commentators will join the fray and continue this important work.
teria for considering new global health laws,21 make
ABR uniquely well-suited for international legal intervention among the range of issues that vie for global
decision-makers’ attention.
Should the decision be made to pursue negotiation of an ABR international legal agreement, then
the exact content of such an agreement will need to
be crafted. Asha Behdinan and colleagues take up
this challenge by assessing ten possible global ABR
policies covering access, conservation and innovation and dividing them into three categories: those
policies that depend on legalization to be effective
(mostly conservation); those policies that would be
strengthened if legalized (mostly access); and those
that could be pursued separately but which might
help mobilize support for implementation of the
other ABR policies if included as part of a grand
bargain (mostly innovation).22 The vitally important
argument is that some conservation policies that are
desperately needed to address ABR might be impossible to implement without the strength of an international legal agreement behind them. The collective
action problems undermining action in some areas
are just too great.
Following selection of the most appropriate international instrument, a decision about the most approantibiotic resistance • summer 2015

tional legal agreement: self-organized venue; World
Health Organization (WHO); World Trade Organization; and United Nations General Assembly (UNGA).
While WHO and UNGA seem particularly promising,
ultimately it is clear that an effective response is probably best coordinated through linked action pursued
through several forums.

Concluding Thoughts
So, what kind of actions must be taken to address the
global threat of ABR? Every article in this series points
towards a common goal: the highest level of global
collective action possible across countries, spanning
sectors, and among all relevant stakeholders. What
legal, political and economic tools might be needed to
achieve this level of action? Each article reveals different lessons to be learned. While an international legal
framework addressing ABR is recommended, such
a framework is still only an implementation vehicle
for other tools — whether those are global standards,
funding agreements, industry engagement, monitored
benchmarks, market incentives, or accountability
mechanisms.
Our goal for this series was to start providing evidence-informed guidance for how states and nonstate actors could muster a comprehensive response
9
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to the global threat of ABR — addressing the access,
conservation and innovation imperatives — while
inspiring new lines of inquiry. We acknowledge this
work is only a start because we know that much
additional research and analysis is needed. Our real
innovation here is having taken a scientific approach
to global strategy whereby we drew upon a range of
disciplines to systematically assess how instruments,
institutions and initiatives could be designed to foster collective action on ABR and maximize impact.24
Our hope is that many more researchers, policymakers, activists, and social commentators will join the
fray and continue this important work. If we wait
too long, we might end up missing today’s policy
window that has been created by the Global Health
Security Agenda launch in February 2014, the adoption of WHO’s Global Action Plan on Antimicrobial
Resistance in May 2015, the White House Forum on
Antibiotic Stewardship and the G7’s communiqué in
June 2015, and the ongoing O’Neill Review on Antimicrobial Resistance in the United Kingdom, among
many other contributing efforts and events.
We have many reasons to be hopeful. In the same
month as this series is published, Professor Otto Cars,
a grandfather of the ABR research field (and co-author
of the second article in this series), was awarded Sweden’s H.M. The King’s Medal for his contributions to
medical science. It demonstrates, in Professor Cars’s
own words, that ABR research “in the twilight zone inbetween science and politics is officially being recognized.”25 We have also started to hear from the world’s
wealthiest countries that they are prepared to use public money to support antibiotics innovation. A major
injection of sustainable financing for R&D of antibiotics could transform the ABR challenge and provide
the necessary political leverage to achieve progress on
the access and conservation imperatives as well.
We conclude by thanking everyone who made this
series possible, including all of our authors, peerreviewers, coordinators, and publishers. We are especially pleased with the timely process at JLME and our
partners’ commitment to open-access publication.
We hope you enjoy reading the series as much as we
enjoyed editing it.
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